Nathaniel Robichaud

Nathaniel Robichaud

Auto-generated profile, based on publicly available information

Nathaniel Robichaud

McGill University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2015 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MBMamatha Bhat
Mamatha Bhat
NRNathaniel Robichaud
Nathaniel Robichaud
LHLaura Hulea
Laura Hulea
NSNahum Sonenberg
Nahum Sonenberg
JPJerry Pelletier
Jerry Pelletier
ITIvan Topisirovic
Ivan Topisirovic

2 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LFLuc Furic
Luc Furic
LRLiwei Rong
Liwei Rong
OLOla Larsson
Ola Larsson
IKIsmaël Hervé Koumakpayi
Ismaël Hervé Koumakpayi
KYKaori Yoshida
Kaori Yoshida
NSNahum Sonenberg
Nahum Sonenberg
Translational regulation plays a critical role in the control of cell growth and proliferation. A key player in translational control is eIF4E, the mRNA 5′ cap-binding protein. Aberrant expression of eIF4E promotes tumorigenesis and has been implicated in cancer development and progression. The activity of eIF4E is dysregulated in cancer. Regulation of eIF4E is partly achieved through phosphorylation. However, the physiological significance of eIF4E phosphorylation in mammals is not clear. Here, we show that knock-in mice expressing a nonphosphorylatable form of eIF4E are resistant to tumorigenesis in a prostate cancer model. By using a genome-wide analysis of translated mRNAs, we show that the phosphorylation of eIF4E is required for translational up-regulation of several proteins implicated in tumorigenesis. Accordingly, increased phospho-eIF4E levels correlate with disease progression in patients with prostate cancer. Our findings establish eIF4E phosphorylation as a critical event in tumorigenesis. These findings raise the possibility that chemical compounds that prevent the phosphorylation of eIF4E could act as anticancer drugs.

9 June 2014 in Oncogene
Verified
Journal Article
Open access
PDF file
NRN Robichaud
N Robichaud
SRS V del Rincon
S V del Rincon
BHB Huor
B Huor
TAT Alain
T Alain
LPL A Petruccelli
L A Petruccelli
NSNahum Sonenberg
Nahum Sonenberg
The progression of cancers from primary tumors to invasive and metastatic stages accounts for the overwhelming majority of cancer deaths. Understanding the molecular events which promote metastasis is thus critical in the clinic. Translational control is emerging as an important factor in tumorigenesis. The messenger RNA (mRNA) cap-binding protein eIF4E is an oncoprotein that has an important role in cancer initiation and progression. eIF4E must be phosphorylated to promote tumor development. However, the role of eIF4E phosphorylation in metastasis is not known. Here, we show that mice in which eukaryotic translation initiation factor 4E (eIF4E) cannot be phosphorylated are resistant to lung metastases in a mammary tumor model, and that cells isolated from these mice exhibit impaired invasion. We also demonstrate that transforming growth factor-beta (TGFβ) induces eIF4E phosphorylation to promote the translation of Snail and Mmp-3 mRNAs, and the induction of epithelial-to-mesenchymal transition (EMT). Furthermore, we describe a new model wherein EMT induced by TGFβ requires translational activation via the non-canonical TGFβ signaling branch acting through eIF4E phosphorylation.

1 March 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
BKBruce W. Konicek
Bruce W. Konicek
JSJennifer R. Stephens
Jennifer R. Stephens
AMAnn M. McNulty
Ann M. McNulty
NRNathaniel Robichaud
Nathaniel Robichaud
RPRobert B. Peery
Robert B. Peery
JGJeremy R. Graff
Jeremy R. Graff
Activation of the translation initiation factor 4E (eIF4E) promotes malignant transformation and metastasis. Signaling through the AKT-mTOR pathway activates eIF4E by phosphorylating the inhibitory 4E binding proteins (4E-BP). This liberates eIF4E and allows binding to eIF4G. eIF4E can then be phosphorylated at serine 209 by the MAPK-interacting kinases (Mnk), which also interact with eIF4G. Although dispensable for normal development, Mnk function and eIF4E phosphorylation promote cellular proliferation and survival and are critical for malignant transformation. Accordingly, Mnk inhibition may serve as an attractive cancer therapy. We now report the identification of a potent, selective and orally bioavailable Mnk inhibitor that effectively blocks 4E phosphorylation both in vitro and in vivo. In cultured cancer cell lines, Mnk inhibitor treatment induces apoptosis and suppresses proliferation and soft agar colonization. Importantly, a single, orally administered dose of this Mnk inhibitor substantially suppresses eIF4E phosphorylation for at least 4 hours in human xenograft tumor tissue and mouse liver tissue. Moreover, oral dosing with the Mnk inhibitor significantly suppresses outgrowth of experimental B16 melanoma pulmonary metastases as well as growth of subcutaneous HCT116 colon carcinoma xenograft tumors, without affecting body weight. These findings offer the first description of a novel, orally bioavailable MNK inhibitor and the first preclinical proof-of-concept that MNK inhibition may provide a tractable cancer therapeutic approach. Cancer Res; 71(5); 1849–57. ©2011 AACR.

29 April 2012 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
BHBarbara Herdy
Barbara Herdy
MJMaritza Jaramillo
Maritza Jaramillo
YSYuri V Svitkin
Yuri V Svitkin
ARAmy B Rosenfeld
Amy B Rosenfeld
MKMariko Kobayashi
Mariko Kobayashi
NSNahum Sonenberg
Nahum Sonenberg

20 February 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NRNathaniel Robichaud
Nathaniel Robichaud
BHBrian E. Hsu
Brian E. Hsu
RIRoman Istomine
Roman Istomine
FAFernando Alvarez
Fernando Alvarez
JBJulianna Blagih
Julianna Blagih
NSNahum Sonenberg
Nahum Sonenberg
Significance: Our findings document mRNA translation in cells of the tumor microenvironment (TME) as a crucial factor in metastatic progression. The results underscore the importance of understanding how translation-targeting therapies affect different cell types within the TME. We provide a rationale for targeting eIF4E phosphorylation in both cancer cells and cells that comprise the TME to halt metastasis and demonstrate the efficacy of this strategy using merestinib, a small molecule targeting the mitogen-activated protein kinase integrating kinases (MNKs). Our findings raise the possibility that a combination of MNK inhibitors with immunotherapy represents a therapeutic opportunity worthy of further investigation for treating cancer metastasis.